Effect of granulocyte colony-stimulating factor on outcomes inpatients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kang, Ka-Won | - |
dc.contributor.author | Kim, Dae Sik | - |
dc.contributor.author | Lee, Se Ryeon | - |
dc.contributor.author | Sung, Hwa Jung | - |
dc.contributor.author | Kim, Seok Jin | - |
dc.contributor.author | Choi, Chul Won | - |
dc.contributor.author | Kim, Byung Soo | - |
dc.contributor.author | Park, Yong | - |
dc.date.accessioned | 2021-09-03T05:34:24Z | - |
dc.date.available | 2021-09-03T05:34:24Z | - |
dc.date.created | 2021-06-16 | - |
dc.date.issued | 2017-06 | - |
dc.identifier.issn | 0145-2126 | - |
dc.identifier.uri | https://scholar.korea.ac.kr/handle/2021.sw.korea/83278 | - |
dc.description.abstract | We analyzed the effects of granulocyte colony-stimulating factor (G-CSF) on outcomes in 315 anthracycline-based induction chemotherapy-treated patients with non-M3 acute myelogenous leukemia (AML). Patients were classified as follows: no G-CSF administration during induction (no G-CSF group; 112 patients); administration immediately upon neutropenia onset (absolute neutrophil counts (ANC)<1000/mu L), but before febrile neutropenia (preemptive group; 74 patients); and administration following febrile neutropenia development (therapeutic group; 129 patients). G-CSF users had a shorter time to ANC recovery than the no G-CSF group (p<0.001). The chemotherapy-induced febrile neutropenia (CIFN) duration was significantly shorter in the preemptive group than in other groups (p<0.001). The incidence of CIFN was not significantly different between preemptive and non-G-CSF users (84.8% versus 82.4%). Preemptive G-CSF administration modestly improved treatment-related mortality (TRM), compared with no G-CSF administration (p=0.076 in multivariate analysis). G-CSF administration did not affect relapse-free or overall survivals or the cumulative relapse incidence among the groups. In conclusion, preemptive G-CSF administration reduced CIFN duration and modestly improved TRM without affecting chemotherapy outcomes. These effects were not observed in the therapeutic group; therefore, initiation of G-CSF during induction therapy before the development of febrile neutropenia may be desirable. (C) 2017 Elsevier Ltd. All rights reserved. | - |
dc.language | English | - |
dc.language.iso | en | - |
dc.publisher | PERGAMON-ELSEVIER SCIENCE LTD | - |
dc.subject | ACUTE MYELOID-LEUKEMIA | - |
dc.subject | MINIMAL RESIDUAL DISEASE | - |
dc.subject | G-CSF | - |
dc.subject | RANDOMIZED-TRIAL | - |
dc.subject | FACTOR RECEPTORS | - |
dc.subject | ELDERLY-PATIENTS | - |
dc.subject | PLUS CYTARABINE | - |
dc.subject | ONCOLOGY-GROUP | - |
dc.subject | GROWTH-FACTORS | - |
dc.subject | DOUBLE-BLIND | - |
dc.title | Effect of granulocyte colony-stimulating factor on outcomes inpatients with non-M3 acute myelogenous leukemia treated with anthracycline-based induction (7+3 regimen) chemotherapies | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Kim, Dae Sik | - |
dc.contributor.affiliatedAuthor | Lee, Se Ryeon | - |
dc.contributor.affiliatedAuthor | Sung, Hwa Jung | - |
dc.contributor.affiliatedAuthor | Choi, Chul Won | - |
dc.contributor.affiliatedAuthor | Kim, Byung Soo | - |
dc.contributor.affiliatedAuthor | Park, Yong | - |
dc.identifier.doi | 10.1016/j.leukres.2017.02.003 | - |
dc.identifier.scopusid | 2-s2.0-85013167741 | - |
dc.identifier.wosid | 000405374700001 | - |
dc.identifier.bibliographicCitation | LEUKEMIA RESEARCH, v.57, pp.1 - 8 | - |
dc.relation.isPartOf | LEUKEMIA RESEARCH | - |
dc.citation.title | LEUKEMIA RESEARCH | - |
dc.citation.volume | 57 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 8 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Oncology | - |
dc.relation.journalResearchArea | Hematology | - |
dc.relation.journalWebOfScienceCategory | Oncology | - |
dc.relation.journalWebOfScienceCategory | Hematology | - |
dc.subject.keywordPlus | ACUTE MYELOID-LEUKEMIA | - |
dc.subject.keywordPlus | MINIMAL RESIDUAL DISEASE | - |
dc.subject.keywordPlus | G-CSF | - |
dc.subject.keywordPlus | RANDOMIZED-TRIAL | - |
dc.subject.keywordPlus | FACTOR RECEPTORS | - |
dc.subject.keywordPlus | ELDERLY-PATIENTS | - |
dc.subject.keywordPlus | PLUS CYTARABINE | - |
dc.subject.keywordPlus | ONCOLOGY-GROUP | - |
dc.subject.keywordPlus | GROWTH-FACTORS | - |
dc.subject.keywordPlus | DOUBLE-BLIND | - |
dc.subject.keywordAuthor | Acute myelogenous leukemia | - |
dc.subject.keywordAuthor | Granulocyte colony-stimulating factor | - |
dc.subject.keywordAuthor | Neutropenia | - |
dc.subject.keywordAuthor | Treatment-related mortality | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
(02841) 서울특별시 성북구 안암로 14502-3290-1114
COPYRIGHT © 2021 Korea University. All Rights Reserved.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.